Multiplex gene expression profile in inflamed mucosa of patients with Crohn’s disease ileal localization: A pilot study

Table 1 Clinical characteristics of patients with ileal Crohn’s disease

Patient	Pt1	Pt2	Pt3	Pt4	Pt5	Pt6	Pt7	Pt8	Pt9	Pt10	Pt11	Pt12	Pt13	Pt14
Localization	L1	L1	L1	L1	L1	L1	L3	L1	L3	L1	L3-L4	L1	L3	L1
of CDa
Age of CD	57	15	53	55	25	31	39	42	16	24	19	18	46	30
onset (yr)
Surgery / relapse	1st	1st	Relapse	1st	Relapse	Relapse	Relapse	1st	Relapse	Relapse	Relapse	Relapse	Relapse	1st
	surgery	surgery		surgery				surgery						surgery
Disease behaviorb	B2	B2, B3	B2	B3	B2, B4	B2	B3	B2	B2	B2	B2	B2	B3	B2
Therapyc	C, F, I, B	F, C	C	No	F, C, I	C, F, I	I, B	F, C	C, I, F, B	C	F, C, B	F, C, I	C, F, B, I	F, C, I
Smoking statusd	No	Cur	No	No	10月10日	No	No	20/30	10月10日	Cur	10月20日	No	No	No
		20/15.5								10
Genotype	wt	R702	wt	hzG881R	wt	wt	wt	wt	hzG881R	R702	No seq	No seq	wt	wt

Localization of Crohn Disease: L1: terminal ileum; L2: colon; L3: ileum colon; L4: upper G (gastrointestinal); Disease behavior: B1: non-stricturing, non-penetrating; B2: stricturing; B3: penetrating; B4: perianal disease. Therapy: M: mesalazine; I: immunosuppressant; B: biologics; C: corticosteroids; Ab: antibiotics. Smoking status: No: non-smoker; Ex: ex-smoker; Cur: current smoker, no. cigs per day / no. yr. MIM: Mendelian inheritance in Man. 1: Transport across epithelia; 2: Immune response; 3: Antimicrobial activity; 4: Different physiological activities.